Sign In

Login

Password

Forgot Password ? Sign Up

Lurasidona (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lurasidona" in Portuguese language version.

refsWebsite
Global rank Portuguese rank
24nih.gov
4th place
8th place
22doi.org
2nd place
4th place
3fda.gov
447th place
869th place
3books.google.com
3rd place
6th place
2europa.eu
68th place
56th place
2drugs.com
399th place
289th place
2web.archive.org
1st place
1st place
1tuasaude.com
low place
936th place
1medscape.com
719th place
598th place
1ds-pharma.com
low place
low place
1psychotherapeuticdrugs.com
low place
low place
1latuda.com
low place
low place
1mdedge.com
low place
low place
1mmm-online.com
low place
low place
1excli.de
low place
low place

books.google.com

doi.org

dx.doi.org

  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet. 382: 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3 
  • Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M. «A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)». The Journal of Clinical Psychiatry. 71: 150–62. PMID 20122369. doi:10.4088/JCP.08m04995gre 
  • Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. «Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression». Journal of Affective Disorders. 121: 106–15. PMID 19903574. doi:10.1016/j.jad.2009.10.007 
  • «Corrigendum». Bipolar Disorders. 10. 451 páginas. 2008. doi:10.1111/j.1399-5618.2008.00585.x 
  • Thase ME. «Quetiapine monotherapy for bipolar depression». Neuropsychiatric Disease and Treatment. 4: 11–21. PMC 2515925Acessível livremente. PMID 18728771. doi:10.2147/ndt.s1162 
  • Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. «Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression». Archives of General Psychiatry. 60: 1079–88. PMID 14609883. doi:10.1001/archpsyc.60.11.1079 
  • Tohen M, Katagiri H, Fujikoshi S, Kanba S. «Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies». Journal of Affective Disorders. 149: 196–201. PMID 23485111. doi:10.1016/j.jad.2013.01.022 
  • Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF. «A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression». The Journal of Clinical Psychiatry. 67: 798–806. PMID 16841630. doi:10.4088/JCP.v67n0514 
  • Azorin JM, Sapin C, Weiller E. «Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses». Journal of Affective Disorders. 145: 62–9. PMID 22868059. doi:10.1016/j.jad.2012.07.013 
  • Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. «Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis». Lancet. 378: 1306–15. PMID 21851976. doi:10.1016/S0140-6736(11)60873-8 
  • Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A (2014). «Lurasidone drug-drug interaction studies: a comprehensive review». Drug Metabolism and Drug Interactions. 29: 191–202. PMID 24825095. doi:10.1515/dmdi-2014-0005 
  • «ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation». Obstetrics and Gynecology. 111: 1001–20. PMID 18378767. doi:10.1097/AOG.0b013e31816fd910 
  • Moore TA. «Schizophrenia treatment guidelines in the United States». Clinical Schizophrenia & Related Psychoses. 5: 40–9. PMID 21459738. doi:10.3371/CSRP.5.1.6 
  • Herrmann N, Mamdani M, Lanctôt KL. «Atypical antipsychotics and risk of cerebrovascular accidents». The American Journal of Psychiatry. 161: 1113–5. PMID 15169702. doi:10.1176/appi.ajp.161.6.1113 
  • Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. «Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia». International Clinical Psychopharmacology. 30: 342–50. PMC 4593468Acessível livremente. PMID 26196189. doi:10.1097/YIC.0000000000000091 
  • Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. «Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study». Depression and Anxiety. 33: 424–34. PMC 5069590Acessível livremente. PMID 26918425. doi:10.1002/da.22479 
  • Moncrieff J. «Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica. 114: 3–13. PMID 16774655. doi:10.1111/j.1600-0447.2006.00787.x 
  • Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M. «Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity». The Journal of Pharmacology and Experimental Therapeutics. 334: 171–81. PMID 20404009. doi:10.1124/jpet.110.167346 
  • Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. «Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test». European Journal of Pharmacology. 572: 160–70. PMID 17662268. doi:10.1016/j.ejphar.2007.06.058 
  • Samalin L, Ben Gharbia M, Garnier M, Llorca PM. «[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]». L'Encephale (em French). 40: 507–17. PMID 25453735. doi:10.1016/j.encep.2014.10.009 
  • Greenberg WM, Citrome L. «Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature». Clinical Pharmacokinetics. 56: 493–503. PMID 27722855. doi:10.1007/s40262-016-0465-5 
  • Caccia S, Pasina L, Nobili A (2012). «Critical appraisal of lurasidone in the management of schizophrenia». Neuropsychiatric Disease and Treatment. 8: 155–68. PMC 3346058Acessível livremente. PMID 22570547. doi:10.2147/NDT.S18059 

drugs.com

ds-pharma.com

europa.eu

ema.europa.eu

excli.de

fda.gov

accessdata.fda.gov

latuda.com

mdedge.com

medscape.com

mmm-online.com

nih.gov

ncbi.nlm.nih.gov

  • Information, National Center for Biotechnology; Pike, U. S. National Library of Medicine 8600 Rockville; MD, Bethesda; Usa, Bethesda (2014). KEY LIMITATIONS. Canadian Agency for Drugs and Technologies in Health. [S.l.: s.n.] 
  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet. 382: 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3 
  • Bawa R, Scarff JR. «Lurasidone: a new treatment option for bipolar depression-a review». Innovations in Clinical Neuroscience. 12: 21–3. PMC 4382136Acessível livremente. PMID 25852975 
  • Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M. «A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)». The Journal of Clinical Psychiatry. 71: 150–62. PMID 20122369. doi:10.4088/JCP.08m04995gre 
  • Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. «Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression». Journal of Affective Disorders. 121: 106–15. PMID 19903574. doi:10.1016/j.jad.2009.10.007 
  • Thase ME. «Quetiapine monotherapy for bipolar depression». Neuropsychiatric Disease and Treatment. 4: 11–21. PMC 2515925Acessível livremente. PMID 18728771. doi:10.2147/ndt.s1162 
  • Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. «Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression». Archives of General Psychiatry. 60: 1079–88. PMID 14609883. doi:10.1001/archpsyc.60.11.1079 
  • Tohen M, Katagiri H, Fujikoshi S, Kanba S. «Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies». Journal of Affective Disorders. 149: 196–201. PMID 23485111. doi:10.1016/j.jad.2013.01.022 
  • Corya SA, Perlis RH, Keck PE, Lin DY, Case MG, Williamson DJ, Tohen MF. «A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression». The Journal of Clinical Psychiatry. 67: 798–806. PMID 16841630. doi:10.4088/JCP.v67n0514 
  • Azorin JM, Sapin C, Weiller E. «Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses». Journal of Affective Disorders. 145: 62–9. PMID 22868059. doi:10.1016/j.jad.2012.07.013 
  • Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. «Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis». Lancet. 378: 1306–15. PMID 21851976. doi:10.1016/S0140-6736(11)60873-8 
  • Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A (2014). «Lurasidone drug-drug interaction studies: a comprehensive review». Drug Metabolism and Drug Interactions. 29: 191–202. PMID 24825095. doi:10.1515/dmdi-2014-0005 
  • «ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation». Obstetrics and Gynecology. 111: 1001–20. PMID 18378767. doi:10.1097/AOG.0b013e31816fd910 
  • Moore TA. «Schizophrenia treatment guidelines in the United States». Clinical Schizophrenia & Related Psychoses. 5: 40–9. PMID 21459738. doi:10.3371/CSRP.5.1.6 
  • Herrmann N, Mamdani M, Lanctôt KL. «Atypical antipsychotics and risk of cerebrovascular accidents». The American Journal of Psychiatry. 161: 1113–5. PMID 15169702. doi:10.1176/appi.ajp.161.6.1113 
  • Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. «Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia». International Clinical Psychopharmacology. 30: 342–50. PMC 4593468Acessível livremente. PMID 26196189. doi:10.1097/YIC.0000000000000091 
  • Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. «Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study». Depression and Anxiety. 33: 424–34. PMC 5069590Acessível livremente. PMID 26918425. doi:10.1002/da.22479 
  • Moncrieff J. «Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica. 114: 3–13. PMID 16774655. doi:10.1111/j.1600-0447.2006.00787.x 
  • Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M. «Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity». The Journal of Pharmacology and Experimental Therapeutics. 334: 171–81. PMID 20404009. doi:10.1124/jpet.110.167346 
  • Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. «Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test». European Journal of Pharmacology. 572: 160–70. PMID 17662268. doi:10.1016/j.ejphar.2007.06.058 
  • Samalin L, Ben Gharbia M, Garnier M, Llorca PM. «[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]». L'Encephale (em French). 40: 507–17. PMID 25453735. doi:10.1016/j.encep.2014.10.009 
  • Greenberg WM, Citrome L. «Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature». Clinical Pharmacokinetics. 56: 493–503. PMID 27722855. doi:10.1007/s40262-016-0465-5 
  • Caccia S, Pasina L, Nobili A (2012). «Critical appraisal of lurasidone in the management of schizophrenia». Neuropsychiatric Disease and Treatment. 8: 155–68. PMC 3346058Acessível livremente. PMID 22570547. doi:10.2147/NDT.S18059 

dailymed.nlm.nih.gov

psychotherapeuticdrugs.com

tuasaude.com

web.archive.org